Haemair has recently completed a Welsh Government SMARTCymru-supported project on ex-vivo support of organs and tissues. The scope of the project is described under “Product Development”, but one of the applications is in organ transplant. Prior to the Covid-19 pandemic, the average time that a patient waits on a kidney transplant waiting list in the UK is typically 30 months. In the USA, it is over 4 years. At the same time, many potential transplant organs are rejected because they appear to be of poor quality. The project aims to develop a device for perfusing donated organs with oxygenated blood to maintain their viability ex-vivo. The device will allow many previously rejected organs to be salvaged and will also improve the success rate for all transplanted organs.
The project consolidates Haemair developments with work previously undertaken by our 100% subsidiary Haemaflow Ltd.
April 26, 2022 4:03 pm
